What's in Medivir's pipeline?

Medivir has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Medivir's portfolio?

Top competitors by shared drug class: Atea Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Tarapeutics Science Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/medivir.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Medivir — Portfolio Competitive Intelligence Brief

Medivir (MVIR.ST) pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

MVIR.ST (Nasdaq Stockholm) 0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ME-609	ME-609	phase 3	HCV NS5B polymerase inhibitor	HCV NS5B RNA-dependent RNA polymerase	Virology/Infectious Disease
acyclovir in ME-609 vehicle	acyclovir in ME-609 vehicle	phase 3	nucleoside analog	viral DNA polymerase	Infectious Diseases

Therapeutic area mix

Infectious Diseases · 1
Virology/Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Atea Pharmaceuticals, Inc. · 1 shared drug class
Bausch & Lomb Incorporated · 1 shared drug class
Tarapeutics Science Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Medivir:

Cite this brief

Drug Landscape (2026). Medivir — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medivir. Accessed 2026-05-14.